The COVID-IYON Study - Study Examining Data Pertaining to Clinical Outcomes and Organisational Responses to the 2020 SARS-CoV-2 Pandemic"
- Conditions
- COVID-19Cancer
- Registration Number
- NCT04581070
- Lead Sponsor
- Cancer Trials Ireland
- Brief Summary
This is a prospective, multisite, descriptive, observational clinical/epidemiological study examining both quantitative and qualitative data pertaining to clinical outcomes and organizational responses to the 2020 SARS-Coronavirus-2 (SARS-CoV-2) pandemic.
- Detailed Description
This study collects real-time observational data regarding the impact of SARS-CoV-2 infection on patients with cancer, and on the functioning and organisation of cancer and malignant haematology services in the Republic of Ireland in response to the 2020 SARS-CoV-2 pandemic.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 4
- Age ≥ 18
- Informed consent has been obtained.
- Cytotoxic chemotherapy, targeted anticancer therapy, immunomodulatory anticancer therapy, hormonotherapy, radiotherapy, oncologic surgery, or other anticancer treatment within the last 12 months (ongoing and completed).
- Tested positive for SARS-CoV-2.
There are no exclusion criteria
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A qualitative description Up til 1 year A qualitative narrative description of national cancer care practises and risk mitigation strategies adopted in response to the SARS-CoV-2 pandemic.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
Mater Misericordiae University Hospital
🇮🇪Dublin, Ireland
University Hospital Limerick
🇮🇪Limerick, Ireland
University Hospital Waterford
🇮🇪Waterford, Ireland